P1-145: Predictors of “long term" survival following surgical treatment of malignant pleural effusion  by Pilling, John et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS608
Special thanks to dr Benfante,dr Bergaglio and dr Tunesi.
P1-143 Mesothelioma and Other Thoracic Malignancy Posters, Mon, Sept 3 
Surgical Resection for Oral Tongue Cancer Pulmonary Metastases, 
a Good Choice?
Mochizuki, Takahiro1 Okumura, Sakae2 Yoshida, Junji1 Ishii, 
Genichiro3 Ishikawa, Yuichi4 Hayashi, Ryuichi5 Kawabata, Kazuyoshi6 
Nakagawa, Ken2 Nagai, Kanji1 
1 Division of Thoracic Surgery, Department of Thoracic Oncology, 
National Cancer Center Hospital East, Kashiwa, Japan 2 Department 
of Thoracic Surgical Oncology, Cancer Institute Hospital, Japanese 
Foundation for Cancer Research, Koto, Japan 3 Pathology Division, 
Research Center for Innovative Oncology, National Cancer Center 
Hospital East, Kashiwa, Japan 4 Department of Pathology, Cancer 
Institute, Japanese Foundation for Cancer Research, Koto, Japan 5 
Division of Head and Neck Surgery, National Cancer Center Hospital 
East, Kashiwa, Japan 6 Department of Head and Neck, Cancer Institute 
Hospital, Japanese Foundation for Cancer Research, Koto, Japan 
Background: The lung is the most common distant metastasis site 
from oral tongue cancer (OTC). However, there have been no reports 
on surgical resection results for pulmonary OTC metastases. The aim 
of this study was to evaluate surgical resection for OTC pulmonary 
metastases efﬁcacy. 
Methods: Between 1977 and 2003, 23 OTC patients who developed 
1 to 3 pulmonary metastases underwent metastasectomy. The clinico-
pathologic features and long-term outcomes were examined. 
Results: The 14 men and 9 women had a median age at the time of pul-
monary metastasectomy of 56 (range; 28-72 years). All 23 patients had 
advanced squamous cell OTC with regional lymph node involvement 
or subsequent regional lymph node metastasis. The median tumor-free 
interval after the initial OTC treatment was 17 months (range: 1-165 
months). Five patients had pneumonectomy, three bilobectomy, 13 
lobectomy, and two wedge resection. Two patients underwent a second 
pulmonary metastasectomy. One patient continues to survive, without 
recurrence at 229 months right now. Twenty-two patients developed 
systemic metastases. The interval to systemic metastasis recurrence 
after pulmonary resection ranged from 1 to 17 months (median, 3.5 
months) and 21 died of OTC at 9.5 months median (range: 1-26 
months) after metastasectomy. One patient was alive with disease at 24 
months after metastasectomy but was lost to follow-up.
Conclusions: Most patients who had OTC pulmonary metastasectomy 
died of the disease within two years. Even for patients with a solitary 
metastasis, surgical resection for OTC pulmonary metastases is not a 
recommended treatment option.
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Background: Soluble mesothelin related proteins (SMRP) have been 
reported as being potential markers for the detection, staging and 
monitoring of treatment of malignant pleural mesothelioma (MPM). In 
order to evaluate the diagnostic accuracy, i.e. sensitivity and speciﬁcity 
of a new ELISA test, we investigated SMRP serum concentrations in 
patients with MPM, primary lung cancer and benign asbestos diseases, 
with a particular focus on differential diagnosis. 
Methods: The study population consisted of 100 newly diagnosed 
MPM patients. They were compared to 75 patients with severe forms 
of asbestosis and 139 patients suffering from untreated primary lung 
cancer. In addition, 29 MPM patient with tumor relapse or progres-
sion after initial therapy were included. SMRP serum concentrations 
were measured by using the newly developed ELISA kit Mesomark™ 
(Fujirebio Diagnostics, Malvern, USA distributed by CIS bio GmbH, 
Berlin, Germany). Statistical analyses (Mann-Whitney U-Test, ROC 
analysis) were performed with SPSS 14.0 (Chicago, Illinois, USA).
Results: SMRP concentrations were found to be signiﬁcantly higher 
in patients suffering from MPM in comparison to benign asbestos dis-
eases (p<0.001) or primary lung cancer (p<0.001). The median values 
(range) were 1.4 (0.2-31.0) nM, 0.9 (0.1-3.3) nM and 0.8 (0-6.0) nM 
respectively. The highest SMRP concentrations were found in patients 
with the epithelial subtype of MPM. However, this was not signiﬁ-
cantly different from the serum concentrations of the sarcomatoid and 
the biphasic subtypes. SMRP tended to increase with the tumour stages 
of MPM. 
At a cutoff value of 1.6 nM SMRP reached a sensitivity of 42% with a 
speciﬁcity of 95% for benign asbestos diseases. Youden index revealed 
an optimal cutoff value of 1.35 nM resulting in a sensitivity of 53% and 
a speciﬁcity of 88%. However, SMRP were also increased in 12.9% 
(cut-off 1.6 nM) or 19.9% (cutoff 1.35nM) of lung cancer patients. 
Receiver operator characteristics (ROC) curves resulted in an area 
under curve (AUC) of 0.72 (95%CI:0.66-0.79) for the discrimination 
between MPM and non-MPM patients (lung cancer and asbestosis). In 
the 29 MPM patients with relapse/progression after an initial therapy, 
SMRP levels were found to be signiﬁcantly higher (Median: 4.2 (0.2-
51.0) nM; p<0.001) compared to the 100 MPM patients without prior 
treatment.
Conclusion: SMRP serum concentration might be an useful measure 
in the diagnostic characterisation of MPM and for the differentiation 
between MPM, benign asbestosis and lung cancer patients. In addition, 
our results indicate that SMRP might be useful in treatment monitoring 
and follow-up. 
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Objective: To investigate prognostic factors following surgical pallia-
tion of malignant pleural effusion (MPE).
Method: We reviewed 280 consecutive patients [109 male, median age 
60 years (range 26 - 89)] undergoing 312 surgical procedures for pallia-
tion of MPE over 72 months. The commonest malignancies were breast 
(29%), malignant pleural mesothelioma (MPM) (25%), lung (12%), 
ovary (9%) and adenocarcinoma of unknown primary (5%). There 
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were 198 thoracoscopic talc pleurodesis, 39 pleuroperitoneal shunts, 
37 pleurodesis via an intercostal drain, 28 pleural biopsies alone and 9 
long term drains. Referring physicians provided survival data. Factors 
signiﬁcance were examined with the log rank test (Kaplein-Meir), those 
signiﬁcant entered a Cox logistic multivariate regression analysis.
Results: Median follow up 1288 days (range 173-2329) 100% com-
plete. Median post-operative survival was 211 days (95%CI 169-253). 
Survival was not signiﬁcantly different by procedure performed or tu-
mour type. MPM had a median survival of 297 days (95%CI 236-358). 
Univarate analysis: Pre-operative leucocytosis, hypoxaemia, raised 
alanine transaminase, hypoalbuminaemia were associated with reduced 
post-operative survival. Multivarate analysis: leucocytosis (p<0.0001), 
hypoxaemia (p=0.014 hypoalbuminaemia (p<0.0001) maintained 
signiﬁcance.
  n
Median  
Survival (Days)
95% C.I. p
WCC >12 53 68 36 - 100 <0.00001
 <12 254 259 207 - 311  
pO2 >9.5 98 317 220 - 414 0.0015
 <9.5 131 130 75 - 185  
Albumin >35 104 667 449 - 885 <0.000001
 <35 202 114 87 - 141
Conclusions: Surgical palliation can be individualised depending upon 
prognosis. Survival following palliation of MPM is the benchmark for 
the results of radical surgery.
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Background: Primitive tracheal tumors are extremely infrequent le-
sions which correspond to 2% of all upper airway neoplastic patholo-
gies and to 0.01% of all malignant lung diseases. The objective is to 
evaluate the survival of these patients according to their histological 
type, length of resection and characteristics of the tracheal margins.
Materials and Methods: retrospective study of a descriptive type 
analyzed over ten year-periods. An examination was conducted of all 
patients diagnosed and treated for a primitive tracheal tumor at “Maria 
Ferrer” Respiratory Rehabilitation Hospital from January 1971 to May 
2006. Out of 48 patients, ranging from 9 to 79 years of age, 29 were 
female and 19 were male.
Results: The most frequent tumor was adenocystic carcinoma, fol-
lowed in frequency by epidermoid carcinoma. The duration of symp-
toms until diagnosis was 10 months and 33% of these patients were 
wrongly treated for asthma. Deobstruction, through rigid bronchoscopy, 
was successful as a bridge towards surgery, and it was reserved for 
use as an exclusive treatment for benign tumors or with a palliative 
criterion in non-resectable tumors. The lowest one-third was the most 
affected tracheal segment.
Conclusions: The best results in this group of patients are related to 
resections which were less than 6 cm long and had negative margins.
P1-147 Mesothelioma and Other Thoracic Malignancy Posters, Mon, Sept 3 
Evaluation of tymic tumors treated with postoperative 
radiotherapy
Yilmaz, Eda B.1 Sarihan, Sureyya1 Bayram, Sami2 Gebitekin, Cengiz2 
1 Uludag University, Faculty of Medicine, Department of Radiation 
Oncology, Bursa, Turkey 2 Uludag University, Faculty of Medicine, 
Department of Thoracic Surgery, Bursa, Turkey 
Background: To retrospectively evaluate the role of postoperative 
radiotherapy (RT) in the management of thymic tumors (TT). 
Methods: From 1995 to 2004, 10 pts (4 females, 6 males) with his-
tologically proven TT (4 tymoma, 6 tymic carcinoma) were treated at 
our department. The median age of the pts was 42 years (19-73 yrs). 
According to Masoaka staging system, there was 1 stage 1, 3 stage 
2, 4 stage 3, 1 stage 4-A, 1 stage 4-B pts. Eight pts were treated with 
total resection and postoperative RT with the median dose of 5940 cGy 
(5040-6000 cGy) in 28-30 fractions. One case who was treated with cu-
rative RT, only received 1620 cGy and 1 cycles of chemotherapy (CT) 
and died in three months. One case who had stage 4-B tymic carcinoma 
was treated with total exicion and metastasectomy and chemotherapy. 
One case who has stage 1 tymoma was treated with RT due to high 
mitoses (6/10) and high proliferative index (Ki-67: 104/1000). The 
histological subtype was in most of cases squamous cell carcinoma. 
Results: All cases were evaluated at January 2007. The median fol-
low-up time was 48 months (3-84 months). Five pts were living at 
the evaluating time. There were 6 complete surgical resections with 
postoperative RT (2 of these also were received CT-median 6 cycles), 
2 incomplete resections followed by chemoradiotherapy (paclitaxel 
60-70 mg/m2/weekly), 1 complete resection and metastasectomy with 
CT (This pt were administered second-line CT and RT), 1 with curative 
RT and CT as the initial treatment. Prior to surgery 1 pt had Myastenia 
Gravis. The median and 2-4 year overall survival rates were 48 months 
(3-84 months), %74, %47, respectively. The median overall survival 
was 34 months (28-49 months) and 48 months (3-84 months) for pts 
with tymoma and tymic carcinoma, respectively. Recurrences were 
seen at mediastinum, and pericardium at the median 47 months (12-54 
months) for 4 pts (4/8, 50%) (2 complete, and 2 incomplete resection, 
and 2 tymic carcinoma and 2 tymoma). Local control rate was 50% in 
the median follow-up time. After the recurrences, pts were treated with 
chemotherapy, surgery and reirradiation with 3960 cGy. The mean and 
2-4 year disease-free survival rates were 47 months (12-62 months), 
75%, 62,5% respectively excluding the pts who have metastatic or died 
at treatment.
Conclusion: The use of surgery and postoperative RT lead to good 
control of residual disease and high overall survival rates. 
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Background: Primary malignant tumors of the trachea are very rare. 
Of these, 50% were squamous cell carcinomas (SCC) and 20% to 35% 
were adenoid cystic carcinomas (ACC). The most frequent site of 
tumour is the lower third of the trachea. Symptoms often mimic astma 
